Clinical Trial Update: Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update reporting safety data for daily esomeprazole in pediatric and adolescent patients with gastroesophageal reflux disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Esomeprazole (Esomeprazole)

Snippet

Sponsor: AstraZeneca | Conditions: Gastroesophageal Reflux Disease (GERD) | Phase 3 | Status: COMPLETED